Biotron Limited (AU:BIT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Biotron Limited has clarified that previous announcements mistakenly referred to ‘blood’ viral loads instead of ‘nasal’ viral loads in their SARS-CoV-2 study, stating this was a typographical error without material impact on the trial’s design. The company also revealed that the delay in the BIT225-012 study’s preliminary results was due to increased workload and a shortage of reagents at Thai laboratories, a situation that came to light during a September 2023 visit by Biotron staff. Biotron is implementing improved processes to avoid future errors in their releases.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
